Cerus Corp (CERS.OQ) Quote| Reuters.com
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.26 (+4.34%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CERS.OQ


Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)


Beta: 1.83
Market Cap(Mil.): $609.25
Shares Outstanding(Mil.): 101.71
Dividend: --
Yield (%): --


  CERS.OQ Industry Sector
P/E (TTM): -- 41.28 34.69
EPS (TTM): -0.65 -- --
ROI: -56.10 11.63 14.13
ROE: -65.41 13.67 15.35

BRIEF-Cerus Corp says Health Canada has approved Intercept blood system for plasma

* Says health canada has approved intercept blood system for plasma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 23 2016

BRIEF-Cerus Corp reports Q1 loss per share $0.17

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 03 2016


  Price Chg
Terumo Corp (4543.T) ¥4,395 +50.00
Grifols SA (GRLS.MC) €19.67 +0.73
Grifols SA (GRLSbn.MC) €14.35 +0.30

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : Stock Traders Daily
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.